REPLY: Reply’s Hybrid Work Research Confirms that “Hybrid work is not a passing trend”, as it Focuses on the Rapid Evolution of Technologies Designed to Support the New Ways of Working
Increased productivity and advanced collaboration are only two of the benefits the new hybrid work models bring and will soon be the new normal in the business world. This is precisely the outcome from the new Hybrid Work research carried with Reply’s Trend SONAR, the proprietary trend detection and monitoring platform based on Artificial Intelligence - with the support of PAC (Teknowlogy Group).
The research estimated the main market trends using sector studies and evidence collected from Reply customers. Data from two different clusters of countries were then compared: the “Europe-5” (Italy, Germany, France, the Netherlands, Belgium) and the “Big-5” (USA, United Kingdom, Brazil, China, India). The aim was to understand the maturity of the market after the spent year and a half of pandemic life.
Companies that have accelerated their digital transformation during the pandemic define the hybrid work model as popular, effective and performing –the very reasons why there will be no turning back.
Aside from a few limitations related to remote collaboration, which technological innovation will increasingly be able to minimise, the new normal does not provide for a full-time return to physical workplaces as before, but rather for greater flexibility and hybrid work paradigms. This approach is expected to revolutionise office design, corporate culture and the overall employee experience. This scenario will benefit employees with better work-life balance and increase of work efficiency, as well as companies: smaller office spaces, flexible working hours, hiring of talent without the need for relocation.
As Filippo Rizzante, Reply CTO, mentions: “The digital world and technology have reshaped the future of the employee experience. Regardless of the specific working context, be it an office or a factory, hybrid work will increasingly be characterised by the support and collaboration of software or hardware based on artificial intelligence. This will be facilitated by greater data literacy and a propensity for digitisation which will not only be the prerogative of developers, but will instead play a key role for the entire workforce. The transition to remote and flexible working models will, to a certain extent, become a permanent fixture and the new corporate culture will have to welcome and embrace the digital dimension as an integral part of daily work routines, facilitating social connections and communication on site, as well as remotely. What’s more, themes such as sustainability and employee well-being will increasingly become an integral part of a company’s DNA.”
To enable the hybrid work scenario, information must be accessible in the cloud and seamless and instant collaboration must be made possible through the adoption of the right tools for each business and activity. At the infrastructure level, cloud computing is not just an option, it is becoming the standard that is driving hybrid architectures. Spending on public and private cloud technologies already represents more than half of the current global infrastructure spending and this is expected to reach two thirds by 2024.
This acceleration and migration is also fuelling investments in productivity tools that consist mostly of cloud-based and intelligent technologies. Reply’s study highlights that among the Europe-5 countries, this market is expected to reach €7.6 billion by 2025. The push towards cloud computing will also drive the market of the countries that make up the Big-5 cluster, which are expected to reach a market of €36 billion.
Another trend highlighted by Reply’s research is the growth of hyperautomation; another approach based on Artificial Intelligence which extends the use of automation to value-added activities. By 2025, nearly half of the largest global companies are expected to support workers with smart technologies designed to assist with complex interactions.
Cybersecurity is also one of the main enabling technologies for hybrid work, precisely because one of the greatest obstacles to this type of work is the potential vulnerability of corporate networks. For this very reason, security is one of the major investment areas in 2021 and it is not expected to be a short-lived trend. It is estimated that by 2025 the market for end-user device security, in other words security solutions for PCs, smartphones, tablets and other corporate devices, will grow by 45% among the Big-5 countries and by 34% among the Europe-5 countries.
A strong focus on sustainability accompanies the Hybrid Work model: Reply’s research shows that the workforce, and in particular the new generations, search for companies that operate with a solid purpose, that act in a responsible and sustainable manner from an environmental point of view and that have the courage to take a stand in social and cultural debates - with clear and measurable corporate ESG standards. The well-being of the workforce, mental health and quality of life are gaining more relevance in the hybrid work environment, alongside physical safety.
Hybrid work has become an essential factor in retaining talent and when facing the great resignation phenomenon, with almost half of under 35s who, according to global data, are considering quitting their jobs if forced to return to the office full time. As the business landscape continues to change, organisations need to improve their existing capabilities and provide access to distance learning platforms. It is estimated that the Big-5’s spending on online learning platforms will increase by 48% by 2025 , reaching €16 billion, while among the Europe-5s this value will reach €2 billion.
The full research can be downloaded here. This new research is part of the Reply Market Research series, which includes the research papers on “From Cloud to Edge” , “Industrial IoT: a reality check” e “Beyond Digital Marketing”.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122005097/en/
Contact information
Media
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Aaron Miani
a.miani@reply.com
Tel. +44 (0)20 7730 6000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
